Novartis has entered into an agreement to acquire Excellergy, a biotechnology company focused on next-generation anti-immunoglobulin E (IgE) therapies for allergic diseases. The deal, valued at up to USD 2 billion, centres on Excellergy's lead asset, EXL-111, a long-acting, high-affinity anti-IgE monoclonal antibody (mAb) currently in Phase I clinical development. The candidate is designed to not only bind free IgE but also to dissociate receptor-bound IgE, potentially leading to faster and more profound inhibition of IgE signalling compared to existing therapies.

The acquisition aligns with Novartis' established expertise in IgE biology and its strategic focus on expanding its portfolio in allergy and immunology. EXL-111 is intended to complement the company's existing offerings and could be developed for a broad range of IgE-mediated allergic conditions, addressing a significant unmet need for more effective and convenient treatments.

According to PharmCube's NextBiopharm® database, EXL-111 ranks 7th globally among IgE-targeted mAbs in terms of development. Click here to request a free trial for NextBiopharm®.